New pill aims to keep high-risk childhood cancer at bay after immunotherapy
NCT ID NCT07278674
First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 21 times
Summary
This study tests whether the drug eflornithine, taken as a pill after standard immunotherapy, can help children with high-risk neuroblastoma live longer without the cancer coming back. About 20 children under 18 who have finished initial treatment and show minimal disease will take eflornithine for maintenance. Researchers will track survival rates and any side effects to see if this approach is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ruijin Hospital Hainan Branch, affiliated with Shanghai Jiao Tong University School of Medicine and Children's Hospital of Shanghai, affiliated with Shanghai Jiao Tong University School of Medicine
Hainan, China
Conditions
Explore the condition pages connected to this study.